中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

140 records (took 0.026 seconds)

    FACILITATION OF RESUSCITATION FROM CARDIAC ARREST BY ERYTHROPOIETIN
    14.
    发明公开
    FACILITATION OF RESUSCITATION FROM CARDIAC ARREST BY ERYTHROPOIETIN 有权
    改良了复苏心脏骤停后促红细胞生成素

    公开(公告)号：EP2349454A1

    公开(公告)日：2011-08-03

    申请号：EP09825478.2

    申请日：2009-11-06

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： GAZMURI, Raul J.

    IPC: A61N1/00

    CPC classification number: A61K38/1816 ,  A61N1/39

    Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes. The main effect of EPO that facilitates resuscitation is the preservation of left ventricular myocardial distensibility leading to improve left ventricular preload and the amount of blood ejected by chest compression. This effect enables higher coronary perfusion pressures to be generated resulting in a higher rate of return of spontaneous circulation and higher survival rates. The very same effect enables the return of spontaneous circulation to occur faster reducing the time a human subject is in cardiac arrest.

    COMPOUNDS AND METHODS FOR MODULATING CLN3 EXPRESSION
    16.
    发明申请
    COMPOUNDS AND METHODS FOR MODULATING CLN3 EXPRESSION 审中-公开

    公开(公告)号：WO2020055917A1

    公开(公告)日：2020-03-19

    申请号：PCT/US2019/050476

    申请日：2019-09-10

    Applicant: IONIS PHARMACEUTICALS, INC. ,  ROSALIND FRANKLIN UNIVERSITY OF MEDICINE & SCIENCE

    Inventor： HASTINGS, Michelle, L. ,  RIGO, Frank

    IPC: A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/113

    Abstract: Provided are compounds, methods, and pharmaceutical compositions for modulating the expression of CLN3 RNA in a cell or animal, and in certain instances modulating the expression of CLN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include poor motor function, seizures, vision loss, poor cognitive function, psychiatric problems, accumulation of autofluorescent ceroid lipopigment, brain tissue dysfunction or cell death, accumulation of mitochondrial ATP synthase subunit C, accumulation of lipofuscin, or astrocyte activation in brain tissue.

    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS IN NEURODEGENERATIVE DISEASE
    17.
    发明申请
    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS IN NEURODEGENERATIVE DISEASE 审中-公开
    神经病变疾病中的替代前期预后转录

    公开(公告)号：WO2006026602A3

    公开(公告)日：2007-11-15

    申请号：PCT/US2005030795

    申请日：2005-08-30

    Applicant: ROSALIND FRANKLIN UNIVERSITY O

    Inventor： POTASHKIN JUDTH ANN

    IPC: C12Q1/68 ,  C07H21/04 ,  C12P19/34

    CPC classification number: C12Q1/6883 ,  C12Q2600/158

    Abstract: The present invention provides a method of diagnosing a neurodegenerative disease in a mammalian subject, preferably a human subject. The method comprises obtaining RNA from the mammalian subject, and assaying the RNA for an increase in the amount of ?fosB mRNA or in ratio of the amount of ?FosB mRNA to the amount of FosB mRNA as compared to that of a control. An increase in the amount of ?FosB mRNA or the ratio of the amount of ?FosB mRNA to the amount of FosB mRNA as compared to that of the control is indicative of the presence of the neurodegenerative disease.

    Abstract translation: 本发明提供了诊断哺乳动物受试者，优选人受试者的神经变性疾病的方法。 该方法包括从哺乳动物受试者获得RNA，并且与对照相比，测定RNA以增加αfosBmRNA的量，或以FosB mRNA的量与FosB mRNA的量的比例。 FosB mRNA的量的增加或与对照组相比，FosB mRNA与FosB mRNA的量的比例的增加表明存在神经变性疾病。

Patent Agency Ranking